VYGR Earnings Date: Nov 9, 2026 (Estimated) — Voyager Therapeutics, Inc.
NASDAQ
Updated
When is VYGR's next earnings date?
Voyager Therapeutics, Inc. (VYGR) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.41 on revenue of $6.3M.
How did VYGR do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Voyager Therapeutics, Inc. posted EPS of -$0.40 versus the -$0.48 estimate, a beat of 23.1%. Revenue was $3.2M against a $4.5M estimate. The stock's 1-day post-earnings move was +4.5%.
How much does VYGR stock move after earnings?
VYGR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.48 | -0.40 | +23.08% | $3.2M | ✅ Beat | +4.47% | +2.88% | +12.14% |
| 2026-05-19 | Q1 2026 | -0.54 | -0.47 | +12.96% | $2.6M | ✅ Beat | +0.57% | +12.93% | +6.90% |
| 2026-03-09 | Q4 2025 | -0.52 | -0.46 | +11.54% | $15.3M | ✅ Beat | +21.65% | +5.11% | -4.62% |
| 2025-11-10 | Q3 2025 | -0.52 | -0.47 | +9.62% | $13.4M | ✅ Beat | +0.71% | -7.09% | +1.42% |
| 2025-08-06 | Q2 2025 | -0.51 | -0.57 | -11.76% | $5.2M | ❌ Miss | -5.29% | +7.35% | +24.71% |
| 2025-03-11 | Q4 2024 | -0.35 | -0.59 | -68.57% | $6.3M | ❌ Miss | +2.27% | -2.14% | -21.66% |
| 2024-11-12 | Q3 2024 | -0.45 | -0.16 | +64.44% | $24.6M | ✅ Beat | -2.05% | -22.84% | -8.49% |
| 2024-08-06 | Q2 2024 | -0.41 | -0.18 | +56.10% | $29.6M | ✅ Beat | -14.04% | -19.41% | -22.59% |
Showing last 8 quarters.